Blog

  • Canon’s RF/EF lens production exceeds 170 million units, extending its world record in interchangeable lens production

    Canon’s RF/EF lens production exceeds 170 million units, extending its world record in interchangeable lens production

    Canon’s RF/EF lens production exceeds 170 million units, extending its world record in interchangeable lens production

    TOKYO, October 22, 2025—Canon Inc. announced today that, in October 2025, Canon reached a historic milestone of producing a cumulative total of 170 million RF and EF interchangeable lenses for its EOS series, extending its world record1 for the highest number of interchangeable camera lenses ever produced.

    A logo commemorating Canon’s achievement
    The RF70-200mm F2.8 L IS USM Z, the 170 millionth lens produced
    The RF70-200mm F2.8 L IS USM Z (released in November 2024),
    the 170 millionth lens produced

    The EF lens was introduced in 1987 as the dedicated lens system for Canon’s EOS autofocus single-lens reflex film camera, debuting simultaneously with the EOS system itself. Since their inception, EF lenses have led the industry by incorporating a series of world-first2 technologies, including the Ultrasonic Motor (USM), Image Stabilizer (IS) technology, and a multilayered Diffractive Optical (DO) element, and have undergone numerous evolutions.

    In 2018, Canon launched the RF lens series, designed for the EOS R mirrorless camera system, which features a large aperture, short back focus, and high-speed communication system to deliver even higher image quality. The RF and EF lens series lineup now includes a total of 108 models3, covering a wide range of focal lengths4 from ultra-wide 10mm to super-telephoto 1200mm. The series also includes the world’s first VR lens5, lenses with built-in power zoom suited for video shooting, and even those compatible with power zoom adapters—expanding the scope of creative expression and meeting the diverse needs of users for both still photography and video.

    EF lens production began at Canon’s Utsunomiya Plant in 1987. Since then, both EF and RF lenses have gained strong support from a wide range of users—from beginners to professionals—leading to steady growth in production volume. Today, Canon manufactures lenses at five sites: Utsunomiya Plant; Canon Inc., Taiwan; Canon Opto (Malaysia) Sdn. Bhd.; Oita Canon Inc.; and Miyazaki Canon Inc. Milestones include 10 million units produced by 1995 and 50 million by 2009. Then in 2014, Canon became the first company in the world to reach 100 million interchangeable camera lenses produced. In October 2025, the company reached 170 million units, leading to the achievement of this world record. The 170 millionth lens produced was the RF70-200mm F2.8 L IS USM Z.

    Canon has maintained the No.16 global market share for digital interchangeable-lens cameras for 22 consecutive years since 2003. Moving forward, Canon will continue to refine its proprietary imaging technologies and further strengthen and expand its lens lineup, pioneering new imaging possibilities and contributing to the continued evolution of photographic and video culture.

    • 1

      Includes EF, EF-S, EF-M, EF Cinema, RF, RF-S, and RF Cinema lenses and extenders. As of October 21, 2025 (according to a survey by Canon)

    • 2

      Among SLR cameras (according to a survey by Canon)

    • 3

      Number of products sold as of October 22, 2025 (including extenders). The number of lens models for sale is different according to
      market figures.

    • 4

      Focal length is 5.2mm to 1200mm when including VR lenses

    • 5

      An interchangeable digital camera lens that enables VR footage with a single camera. Among interchangeable lens digital cameras released as of October 5, 2021 (according to a survey by Canon)

    • 6

      Refers to unit share (according to a survey by Canon)

    Highlights in the development of the RF/EF Lens Series

    EF75-300mm f/4-5.6 IS USM
    EF75-300mm f/4-5.6 IS USM
    (September 1995)
    EF400mm f/4 DO IS USM
    EF400mm f/4 DO IS USM
    (December 2001)
    EF24mm f/1.4L II USM
    EF24mm f/1.4L II USM
    (December 2008)

    The EF lens, which was introduced alongside EOS in March 1987, has adopted a variety of world-first technologies, including Image Stabilizer (IS) technology, featured in the EF75-300mm f/4-5.6 IS USM released in 1995; a multilayered Diffractive Optical (DO) element, used in the EF400mm f/4 DO IS USM launched in 2001; and Subwavelength Structure Coating (SWC)7, applied to the EF24mm f/1.4L II USM released in 2008.

    EOS VR SYSTEM RF5.2mm F2.8 L DUAL FISHEYE
    EOS VR SYSTEM RF5.2mm F2.8 L DUAL FISHEYE
    (December 2021)
    RF24-105mm F2.8 L IS USM Z
    RF24-105mm F2.8 L IS USM Z
    *shown with power zoom adapter
    (December 2023)
    RF85mm F1.4 L VCM
    RF85mm F1.4 L VCM
    (September 2025)

    In 2021, Canon launched the EOS VR System, a VR video system consisting of a mirrorless camera8, dedicated lens, and PC software, thereby creating a 3D 180° VR video through an interchangeable lens camera. In 2024, Canon began rolling out a new series of hybrid lenses equipped with iris rings, designed to meet the needs of both still photography and professional video production. For zoom lenses, the company has also launched RF24-105mm F2.8 L IS USM Z and RF70-200mm F2.8 L IS USM Z which are compatible with power zoom adapters. For single focus lenses, the company released F1.4 L hybrid prime lens series that unified the size and ring and button position across models. In September 2025, Canon launched RF85mm F1.4 L VCM, the fifth model in this series, demonstrating that it can meet demands in line with the changing times.

    • 7

      A special coating with advanced anti-reflective properties

    • 8

      For applicable cameras, please visit the official Canon website.

    Continue Reading

  • Elizabeth Olsen On Only Acting In Movies With Theatrical Release & Why She’d “Jump” At Chance To Play Wanda In MCU Again

    Elizabeth Olsen On Only Acting In Movies With Theatrical Release & Why She’d “Jump” At Chance To Play Wanda In MCU Again

    Elizabeth Olsen is sharing her passion for moviemaking and, in a recent interview, explained why seeing films in a theater is essential.

    The actress recently mentioned that she would rather star in films that get theatrical…

    Continue Reading

  • LME Week takeaways: Metals find their footing | articles

    LME Week takeaways: Metals find their footing | articles

    Gold drew attention during LME Week, with prices up by around 60% this year. The rally has been driven by uncertainties over global trade, heightened geopolitical tensions, US fiscal stability and the Fed’s independence. The start of the Fed’s easing cycle also boosted gold, which doesn’t pay any interest. The rally has been driven by physical buying, with central banks and private investors accumulating gold at record volumes.

    But after a weeks-long rally that saw the precious metal hitting successive record highs, gold slid the most in 12 years this week. This signalled that some momentum might have been stretched. Gold was dragged down by a combination of factors, including profit-taking across precious metals, easing seasonal demand from Diwali, positive trade talks between China and the US, uncertainty over investor positions amid the US government shutdown, and a stronger dollar. The pullback underscores the risk that the rally might have moved ahead of underlying fundamentals.

    But despite this sharp pullback, gold’s outlook remains constructive, underpinned by macro uncertainty and diversification demand.

    The shift in central banks’ purchases has been structural, with the pace of buying doubling in 2022 following Russia’s invasion of Ukraine. Central banks’ appetite for gold is driven by concerns from countries about Russian-style sanctions on their foreign assets, as well as shifting strategies on currency reserves. The top year-to-date buyer has been the National Bank of Poland, and it just announced it aims to increase its reserves from 21% to 30%.

    ETFs have been another powerful force behind gold’s record-breaking rally this year, with holdings surging in recent weeks. In fact, gold ETFs have added as much gold in September alone as central banks did during the first quarter of this year combined, according to the World Gold Council. With ETF holdings still shy of a peak hit in 2022, there could be room for further increases.

    The downside should be limited, supported by geopolitical concerns, sustained central bank demand and expectations of further monetary easing, although near-term volatility may persist. For now, gold’s pullback looks like a healthy correction within a still-positive trend.

    Continue Reading

  • If these OnePlus 15 rumors are true, I’m worried for Samsung and Google in 2026

    If these OnePlus 15 rumors are true, I’m worried for Samsung and Google in 2026

    OnePlus/ZDNET

    Follow ZDNET: Add us as a preferred source on Google.


    ZDNET’s key takeaways

    • The OnePlus 15 is launching in China soon, and most specs may carry over to the US.
    • Rumors point to a much larger battery, a smoother display, and…

    Continue Reading

  • IONIQ 9 – Crafted for comfort and companionship

    IONIQ 9 – Crafted for comfort and companionship

    Ground-breaking design, outstanding performance

    As the first-ever three-row SUV in the IONIQ lineup, the IONIQ 9 left a lasting impression during its global debut in Los Angeles. Guests and members of the international press were immediately impressed by the IONIQ 9’s aerodynamic design, commanding presence, and outstanding electric performance.

    The IONIQ 9 breaks boundaries in many ways: exterior design elements, such as its sleek silhouette, tapered boat-tail form, and smooth, single-curved roofline, demonstrate a new aerodynamic architecture and bold design step. But where the concept of bringing people together is most on display is IONIQ 9’s cozy and interaction-enhancing interior. Once inside, both drivers and passengers are greeted with a roomy, harmonious space that feels more like a luxurious lounge than a car cockpit. Soothing colors, innovative materials, and ride-enhancing technology come together to create a unique atmosphere that people want to interact in.


    Continue Reading

  • The Best Wedding Dresses From New York Bridal Fashion Week Fall 2026

    The Best Wedding Dresses From New York Bridal Fashion Week Fall 2026

    New York Bridal Fashion Week Fall 2026 was packed with hundreds of gowns, minis, and sets that will be filling bridal salons and showrooms next spring. Every designer brought their own perspective, providing to-be-weds of every sartorial leaning…

    Continue Reading

  • Our brains evaluate food within milliseconds, long before we’ve decided to eat it

    Our brains evaluate food within milliseconds, long before we’ve decided to eat it

    Imagine you’re at the grocery store, standing before a selection of snacks. Seemingly without thinking, you skip over the rice crackers to pick out a bag of chips.

    These types of choices are called dietary decisions. It’s how we consider many different aspects of a food – including tastiness, healthiness and price – in order to decide what to buy and what to eat.

    It’s not well understood how our brains use all these different bits of information when making food choices. When does information about each aspect of the food become available to our brains to consider? That’s what we set out to investigate.

    In our new paper published in the journal Appetite, we show how, just hundreds of milliseconds after we have seen a food, many different attributes are reflected in brain activity. This happens extremely fast, long before a person can consciously decide whether or not to buy or eat the food.

    Peering inside the brain

    Naturally, how fast our brains process the different aspects of foods will affect our dietary decisions.

    For example, studies have reported that we may process how tasty we find a food more quickly than how healthy it is. This quirk can bias our choices toward foods that taste better over those that are healthier. Junk foods – tasty but not necessarily good for us – have an edge here.

    To investigate how quickly we process different aspects of foods, we used electroencephalography, a method that allows us to record electrical brain activity with millisecond precision.

    We recorded people’s brain activity while showing them images of various foods, such as snack items, meats, fruits and sweets. We also asked people to rate each food on many different aspects, such as healthiness, tastiness, calorie content, familiarity, and how much they would like to eat the food.

    An example of a food item presented in the study.
    Chae et al., 2025

    We then used machine learning techniques to compare patterns of brain activity (how different the brain responses were to different food items) with the patterns of ratings (how differently those foods were rated).

    This allowed us to test whether foods that had the largest differences in ratings also had the largest differences in brain activity. In other words – was information about food attributes actually reflected in people’s brain activity?

    As it turned out, it was.

    Information about different aspects of foods, such as healthiness, calorie content and familiarity, were reflected in the brain activity as early as 200 milliseconds after the food image was presented on the screen.

    These rapid brain responses occurred before people could be consciously aware of the food they were seeing. Other aspects of foods, such as tastiness and willingness to eat the food, were reflected in the brain activity slightly later.

    Choosing before choosing

    These findings suggest that various aspects of foods may grab our attention early and help guide our dietary decisions. The brain assesses many different aspects of foods automatically and with similar timing, shaping our food choices before we’re even aware of them.

    Surprisingly, we found that the healthiness of foods was represented in the brain activity earlier than tastiness. While this contradicted some previous findings, our machine learning techniques may have been more sensitive to detect subtle patterns of brain activity associated with each attribute.

    There were also similarities in the way people judged different aspects of a food. For example, foods that were less familiar were also rated as being less tasty.

    From these patterns of similarity, we identified two key food dimensions that may be particularly important when our brains evaluate foods. The first one is the “processed” dimension: how natural or processed a food is. The second is the “appetising” dimension, which taps into how tasty and familiar we find a food.

    Both were reflected in patterns of brain activity very rapidly, about 200ms after seeing a food item.

    There’s more than the eye can see

    Our findings are most relevant to situations where we only rely on the visual features of foods, such as when ordering groceries or meals online, or using a picture menu at a restaurant. They shed light on how people make snap judgements at the supermarket or on food delivery apps.

    Our brain imaging approach can also be used to test if certain strategies, such as deliberately focusing on the healthiness of foods, might change how foods are rapidly appraised and help us improve our choices.

    While we used food images in this study, other senses are also important for dietary decisions. Smelling a mango or hearing the sizzle of a frying burger patty are likely processed quickly by the brain as well.

    The next step will be to look into these other sensory features of foods, to see how the brain processes not just images of food, but the real deal when placed in front of us.

    Continue Reading

  • Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent’s Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

    • The collaboration combines Innovent’s proven immuno-oncology (“IO”) and antibody-drug conjugate (“ADC”) R&D capability and Takeda’s experience in global oncology drug development to accelerate Innovent’s two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.
    • Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.
    • Innovent will grant Takeda exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China.
    • Innovent will grant Takeda an exclusive option for the rights for IBI3001 (EGFR/B7H3 ADC) outside Greater China.
    • Innovent will receive a US$1.2 billion upfront payment including a strategic equity investment of US$100 million at premium, and potential milestones for a total deal value of up to US$11.4 billion, and royalties.
    • Innovent to host conference calls and webcasts at 9:00 a.m. HKT (Chinese session) and 9:00 p.m. HKT (English session) on Wednesday, October 22, 2025.

    SAN FRANCISCO and SUZHOU, China, Oct. 21, 2025 /PRNewswire/ — Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation IO and ADC cancer therapies, with the goal of developing potentially transformative cancer treatments to benefit patients worldwide.

    This partnership aims to leverage key synergies and accelerate the global development of several investigational medicines within Innovent’s IO+ADC pipeline, including: IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein demonstrating robust anti-tumor activity and potential to be a foundational next-generation IO therapy that is currently in Phase 3 clinical stage; IBI343, a potentially best-in-class CLDN18.2 ADC currently in Phase 3 clinical stage; and IBI3001, a first-in-class EGFR/B7H3 bispecific ADC currently in Phase 1 clinical stage.

    Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, stated, 

    “We believe that developing innovative IO and ADC will be a key direction for redefining cancer treatment worldwide. This landmark collaboration with Takeda brings together our three next-generation assets. With clear, aligned development plans, Innovent’s deep understanding of these assets, combined with Takeda’s extensive experience and strong development and commercialization capabilities, we are committed to delivering these promising medicines to patients worldwide as quickly as possible. This collaboration is also a crucial step in fulfilling Innovent’s strategic roadmap as we expand our global footprint, with the goal of becoming a leading global biopharmaceutical company.”

    “We are excited to partner with Innovent, an accomplished team with deep expertise in next-generation immuno-oncology and ADC biology,” said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda.  “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors. We are energized by the progress made by Innovent  to date and look forward to collaborating to unlock the potential of these programs. Our global research and development expertise  and commercialization capabilities will enable us to accelerate the delivery of these investigational medicines to patients. These two programs have the potential to be transformative for our oncology portfolio and significantly enhance Takeda’s growth potential post-2030.”

    IBI363 (PD-1/IL-2α-bias): Global Joint Development and Commercialization Collaboration

    IBI363, developed by Innovent Biologics, is a potentially first-in-class PD-1/IL-2α-biased bispecific antibody fusion protein that simultaneously blocks the PD-1/PD-L1 pathway and activates the IL-2 pathway. Innovent has shown that IBI363, with an IL-2 receptor alpha focused approach, selectively expands tumor-specific CD8+ T cells that increase tumor cell killing efficiency without activating or expanding the toxicity related to peripheral T cells, which results in a better safety profile than what is seen with traditional IL-2s. Phase 1b/2 results presented at ASCO 2025 have demonstrated outstanding tumor responses and preliminary survival benefits of IBI363 across immunotherapy-resistant lung cancer, “cold tumors” such as acral and mucosal melanoma, and MSS colorectal cancer. IBI363 is now in registrational clinical development, including a global Phase 3 study in second line sqNSCLC that is expected to begin in the coming months; the China NMPA has granted Breakthrough Designation (BTD) and U.S. FDA has granted Fast Track Designation (FTD) for this indication.

    According to the agreement, Innovent and Takeda will co-develop IBI363 globally, sharing development costs 40/60 (Innovent/Takeda). In the U.S., Innovent and Takeda will co-commercialize IBI363, sharing the U.S. profit or loss 40/60. Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent will grant Takeda commercialization rights outside Greater China and the U.S. Takeda will have global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S. Takeda will pay Innovent potential development and sales milestones outside Greater China, and tiered royalties up to high-teens on net sales outside Greater China and the U.S.

    This collaboration aims to explore and maximize IBI363’s potential as a new IO backbone therapy through aligned co-development plans. Building on its already robust clinical data of over 1,200 treated patients, IBI363 will be initially developed globally in non-small cell lung cancer (“NSCLC”) and colorectal cancer (“CRC”), including in the first-line settings. Additionally, Takeda and Innovent plan to expand IBI363’s clinical development to additional indications.

    IBI343 (CLDN18.2 ADC): Global License for Development and Commercialization

    IBI343, developed by Innovent Biologics, is an innovative TOPO1 inhibitor ADC targeting CLDN18.2. Clinical data show a favorable safety profile and encouraging efficacy signals. It is currently being evaluated in a Phase 3 clinical trial in gastric/gastroesophageal cancers (G-HOPE-001) in China and Japan, and was granted Breakthrough Designation in China. IBI343 also completed a global Phase 1/2 trial in previously treated pancreatic ductal adenocarcinoma (PDAC) and has received Breakthrough Designation in China for this indication. It has also received Fast Track Designation from the U.S. FDA for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) that has relapsed and/or is refractory to one prior line of therapy.

    Innovent will grant Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China. Takeda plans to advance the development of IBI343 and expand into first-line gastric and pancreatic cancer settings.

    Takeda will make potential milestone payments, and tiered royalties on net sales up to high-teens for the license of IBI343.

    IBI3001 (EGFR/B7H3 ADC): Option to Global License for Development and Commercialization

    IBI3001, currently in a Phase 1 clinical trial, is a first-in-class bispecific ADC targeting B7-H3 and EGFR. It combines multiple anti-tumor mechanisms, including enhanced EGFR blockade, receptor-mediated internalization, and strong ADC-mediated cytotoxicity, with a high safety margin demonstrated in preclinical models.

    Innovent will grant Takeda an exclusive option to license global development, manufacturing, and commercialization rights for IBI3001 outside of Greater China. If exercised, Takeda will pay Innovent an exercise fee, potential milestone payments, and tiered royalties on net sales up to mid-teens.

    Financial Highlights: Total Deal Value up to $11.4Billion

    Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance, at HK$112.56 per share, a 20% premium to the Innovent 30-trading-day weighted average share price.

    Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent will also receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses.

    Innovent will host conference calls and webcasts at 9:00 a.m. HKT (Chinese session) and 9:00 p.m. HKT (English session) on Wednesday, October 22, 2025.Details of the conference call dial-in and the webcast link will be provided on the company website at https://investor.innoventbio.com/en/investors/webcasts-and-presentations/. A replay will also be available on the website shortly after the event.

    Morgan Stanley Asia Limited serves as the exclusive financial advisor to Innovent Biologics in relation to this transaction.

    About Innovent Biologics

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

    Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement:  Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    Forward-looking statement of Innovent Biologics

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

    Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    SOURCE Innovent Biologics

    Continue Reading

  • Pindi declared model district for dengue control as capital reports 25 new cases – Dawn

    1. Pindi declared model district for dengue control as capital reports 25 new cases  Dawn
    2. Dengue cases spike in twin cities despite drop in temperature  Dawn
    3. Karachi most affected by dengue in Sindh  The Express Tribune
    4. Due to mosquito bites!  Minute…

    Continue Reading

  • Govt downplays dengue outbreak, confirms 276 new cases in October – Dawn

    1. Govt downplays dengue outbreak, confirms 276 new cases in October  Dawn
    2. Karachi most affected by dengue in Sindh  The Express Tribune
    3. Due to mosquito bites!  Minute Mirror
    4. Pakistan: Government apathy and data manipulation deepen Sindh’s medical…

    Continue Reading